59 studies found for:    acute myelomonocytic leukemia | Open Studies
Show Display Options
Rank Status Study
21 Recruiting A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: No interventions
22 Recruiting CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Conditions: Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
23 Not yet recruiting WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: WEE1 Inhibitor AZD1775
24 Recruiting Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
Interventions: Other: Antitumor Drug Screening Assay;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Other: Pharmacological Study;   Drug: Ponatinib Hydrochloride;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate
25 Recruiting Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia-2;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Drug: Idarubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pomalidomide
26 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention:
27 Recruiting Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Condition: Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: lenzilumab
28 Recruiting Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: azacitidine;   Biological: donor lymphocyte infusion
29 Recruiting Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Secondary Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Biological: Indium In 111 Anti-CD45 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
30 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   CD45-Positive Neoplastic Cells Present;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Radiation: Iodine I 131 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
31 Recruiting Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia
Condition: Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Tipifarnib
32 Recruiting Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Condition: Juvenile Myelomonocytic Leukemia
Intervention: Procedure: Stem Cell Transplant
33 Recruiting Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Conditions: Leukemia;   Acute Myeloid Leukemia
Interventions: Drug: Selinexor;   Drug: Sorafenib
34 Recruiting Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies
Conditions: Myeloablative Conditioning;   HLA-mismatched Bone Marrow Transplantation;   Graft Survival;   Transplantion, Bone Marrow
Interventions: Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Busulfan;   Other: Unmanipulated Bone Marrow;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
35 Recruiting Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Conditions: Non-Hodgkin's Lymphoma;   Acute Leukemia in Remission;   Chronic Myeloid Leukemia;   Primary Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndromes;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Drug: Fludarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Radiation: Total body irradiation (TBI);   Procedure: Peripheral Blood Hematopoietic Cell Transplantation (HCT);   Drug: Sirolimus (SIR);   Drug: Mycophenolate mofetil (MMF);   Drug: Granulocyte-colony stimulating factor (G-CSF)
36 Recruiting Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Lymphoma,Non-Hodgkin;   Lymphoma, Hodgkin;   Lymphoma, Follicular;   Marginal Zone Lymphoma;   Large Cell Lymphoma;   Mantle-Cell Lymphoma;   Gray Zone Lymphoma;   Burkitt Lymphoma
Interventions: Drug: Bendamustine;   Drug: Cyclophosphamide
37 Recruiting Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoid Leukemia;   Myeloproliferative Disease;   Myelodysplastic Syndrome;   Chronic Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Interventions: Drug: ARM A Cyclophosphamide;   Drug: ARM B Calcineurin inhibitor and methotrexate
38 Recruiting Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Conditions: AML;   CMML;   MDS
Intervention: Drug: FF-10501-01
39 Not yet recruiting Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Conditions: Acute Leukemias;   Chronic Leukemias;   Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia
Intervention: Drug: Busulfan/Cyclophosphamide
40 Recruiting Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemia/Lymphoma;   Myelodysplasia;   Acute Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-59) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.